COVID-19, asthma, and biological therapies: what we need to know
Managing patients with severe asthma during the coronavirus pandemic and COVID-19 is a challenge. Authorities and physicians are still learning how COVID-19 affects people with underlying diseases, and severe asthma is not an exception. Unless relevant data emerge that change our understanding of th...
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Artículo |
| Lenguaje: | inglés |
| Publicado: |
2020
|
| Materias: | |
| Acceso en línea: | http://eprints.uanl.mx/20097/1/1-s2.0-S1939455120300296-main.pdf |
| _version_ | 1824415748086300672 |
|---|---|
| author | Morais Almeida, Mario Aguiar, Rita Martin, Bryan Ansotegui, Ignacio J. Ebisawa, Motohiro Arruda, L. Karla Caminati, Marco Canonica, Giorgio Walter Carr, Tara Chupp, Geoffrey Corren, Jonathan Dávila, Ignacio Park, Hae Sim Hanania, Nicola A. Rosenwasser, Lanny Sánchez Borges, Mario Virchow, J. Christian Yáñez, Anahí Bernstein, Jonathan A. Caraballo, Luis R. Chang, Yoon Seok Chikhladze, Manana Fiocchi, Alessandro González Díaz, Sandra Nora Tanno, Luciana Kase Levin, Michael Ortega Martell, José Antonio Passalacqua, Giovanni Peden, David B. Rouadi, Philip W. Sublett, James L. Wong, Gary W.K. Bleecker, Eugene R. |
| author_facet | Morais Almeida, Mario Aguiar, Rita Martin, Bryan Ansotegui, Ignacio J. Ebisawa, Motohiro Arruda, L. Karla Caminati, Marco Canonica, Giorgio Walter Carr, Tara Chupp, Geoffrey Corren, Jonathan Dávila, Ignacio Park, Hae Sim Hanania, Nicola A. Rosenwasser, Lanny Sánchez Borges, Mario Virchow, J. Christian Yáñez, Anahí Bernstein, Jonathan A. Caraballo, Luis R. Chang, Yoon Seok Chikhladze, Manana Fiocchi, Alessandro González Díaz, Sandra Nora Tanno, Luciana Kase Levin, Michael Ortega Martell, José Antonio Passalacqua, Giovanni Peden, David B. Rouadi, Philip W. Sublett, James L. Wong, Gary W.K. Bleecker, Eugene R. |
| author_sort | Morais Almeida, Mario |
| collection | Repositorio Institucional |
| description | Managing patients with severe asthma during the coronavirus pandemic and COVID-19 is a challenge. Authorities and physicians are still learning how COVID-19 affects people with underlying diseases, and severe asthma is not an exception. Unless relevant data emerge that change our understanding of the relative safety of medications indicated in patients with asthma during this pandemic, clinicians must follow the recommendations of current evidence-based guidelines for preventing loss of control and exacerbations. Also, with the absence of data that would indicate any potential harm, current advice is to continue the administration of biological therapies during the COVID-19 pandemic in patients with asthma for whom such therapies are clearly indicated and have been effective. For patients with severe asthma infected by SARS-CoV-2, the decision to maintain or postpone biological therapy until the patient recovers should be a case-by-case based decision supported by a multidisciplinary team. A registry of cases of COVID-19 in patients with severe asthma, including those treated with biologics, will help to address a clinical challenge in which we have more questions than answers. |
| format | Article |
| id | eprints-20097 |
| institution | UANL |
| language | English |
| publishDate | 2020 |
| record_format | eprints |
| spelling | eprints-200972024-12-11T16:23:59Z http://eprints.uanl.mx/20097/ COVID-19, asthma, and biological therapies: what we need to know Morais Almeida, Mario Aguiar, Rita Martin, Bryan Ansotegui, Ignacio J. Ebisawa, Motohiro Arruda, L. Karla Caminati, Marco Canonica, Giorgio Walter Carr, Tara Chupp, Geoffrey Corren, Jonathan Dávila, Ignacio Park, Hae Sim Hanania, Nicola A. Rosenwasser, Lanny Sánchez Borges, Mario Virchow, J. Christian Yáñez, Anahí Bernstein, Jonathan A. Caraballo, Luis R. Chang, Yoon Seok Chikhladze, Manana Fiocchi, Alessandro González Díaz, Sandra Nora Tanno, Luciana Kase Levin, Michael Ortega Martell, José Antonio Passalacqua, Giovanni Peden, David B. Rouadi, Philip W. Sublett, James L. Wong, Gary W.K. Bleecker, Eugene R. RC Medicina Interna, Psiquiatría, Neurología Managing patients with severe asthma during the coronavirus pandemic and COVID-19 is a challenge. Authorities and physicians are still learning how COVID-19 affects people with underlying diseases, and severe asthma is not an exception. Unless relevant data emerge that change our understanding of the relative safety of medications indicated in patients with asthma during this pandemic, clinicians must follow the recommendations of current evidence-based guidelines for preventing loss of control and exacerbations. Also, with the absence of data that would indicate any potential harm, current advice is to continue the administration of biological therapies during the COVID-19 pandemic in patients with asthma for whom such therapies are clearly indicated and have been effective. For patients with severe asthma infected by SARS-CoV-2, the decision to maintain or postpone biological therapy until the patient recovers should be a case-by-case based decision supported by a multidisciplinary team. A registry of cases of COVID-19 in patients with severe asthma, including those treated with biologics, will help to address a clinical challenge in which we have more questions than answers. 2020 Article PeerReviewed text en cc_by_nc_nd http://eprints.uanl.mx/20097/1/1-s2.0-S1939455120300296-main.pdf http://eprints.uanl.mx/20097/1.haspreviewThumbnailVersion/1-s2.0-S1939455120300296-main.pdf Morais Almeida, Mario y Aguiar, Rita y Martin, Bryan y Ansotegui, Ignacio J. y Ebisawa, Motohiro y Arruda, L. Karla y Caminati, Marco y Canonica, Giorgio Walter y Carr, Tara y Chupp, Geoffrey y Corren, Jonathan y Dávila, Ignacio y Park, Hae Sim y Hanania, Nicola A. y Rosenwasser, Lanny y Sánchez Borges, Mario y Virchow, J. Christian y Yáñez, Anahí y Bernstein, Jonathan A. y Caraballo, Luis R. y Chang, Yoon Seok y Chikhladze, Manana y Fiocchi, Alessandro y González Díaz, Sandra Nora y Tanno, Luciana Kase y Levin, Michael y Ortega Martell, José Antonio y Passalacqua, Giovanni y Peden, David B. y Rouadi, Philip W. y Sublett, James L. y Wong, Gary W.K. y Bleecker, Eugene R. (2020) COVID-19, asthma, and biological therapies: what we need to know. World Allergy Organization Journal, 13 (5). p. 100126. ISSN 1939-4551 http://doi.org/10.1016/j.waojou.2020.100126 doi:10.1016/j.waojou.2020.100126 |
| spellingShingle | RC Medicina Interna, Psiquiatría, Neurología Morais Almeida, Mario Aguiar, Rita Martin, Bryan Ansotegui, Ignacio J. Ebisawa, Motohiro Arruda, L. Karla Caminati, Marco Canonica, Giorgio Walter Carr, Tara Chupp, Geoffrey Corren, Jonathan Dávila, Ignacio Park, Hae Sim Hanania, Nicola A. Rosenwasser, Lanny Sánchez Borges, Mario Virchow, J. Christian Yáñez, Anahí Bernstein, Jonathan A. Caraballo, Luis R. Chang, Yoon Seok Chikhladze, Manana Fiocchi, Alessandro González Díaz, Sandra Nora Tanno, Luciana Kase Levin, Michael Ortega Martell, José Antonio Passalacqua, Giovanni Peden, David B. Rouadi, Philip W. Sublett, James L. Wong, Gary W.K. Bleecker, Eugene R. COVID-19, asthma, and biological therapies: what we need to know |
| thumbnail | https://rediab.uanl.mx/themes/sandal5/images/online.png |
| title | COVID-19, asthma, and biological therapies: what we need to know |
| title_full | COVID-19, asthma, and biological therapies: what we need to know |
| title_fullStr | COVID-19, asthma, and biological therapies: what we need to know |
| title_full_unstemmed | COVID-19, asthma, and biological therapies: what we need to know |
| title_short | COVID-19, asthma, and biological therapies: what we need to know |
| title_sort | covid 19 asthma and biological therapies what we need to know |
| topic | RC Medicina Interna, Psiquiatría, Neurología |
| url | http://eprints.uanl.mx/20097/1/1-s2.0-S1939455120300296-main.pdf |
| work_keys_str_mv | AT moraisalmeidamario covid19asthmaandbiologicaltherapieswhatweneedtoknow AT aguiarrita covid19asthmaandbiologicaltherapieswhatweneedtoknow AT martinbryan covid19asthmaandbiologicaltherapieswhatweneedtoknow AT ansoteguiignacioj covid19asthmaandbiologicaltherapieswhatweneedtoknow AT ebisawamotohiro covid19asthmaandbiologicaltherapieswhatweneedtoknow AT arrudalkarla covid19asthmaandbiologicaltherapieswhatweneedtoknow AT caminatimarco covid19asthmaandbiologicaltherapieswhatweneedtoknow AT canonicagiorgiowalter covid19asthmaandbiologicaltherapieswhatweneedtoknow AT carrtara covid19asthmaandbiologicaltherapieswhatweneedtoknow AT chuppgeoffrey covid19asthmaandbiologicaltherapieswhatweneedtoknow AT correnjonathan covid19asthmaandbiologicaltherapieswhatweneedtoknow AT davilaignacio covid19asthmaandbiologicaltherapieswhatweneedtoknow AT parkhaesim covid19asthmaandbiologicaltherapieswhatweneedtoknow AT hananianicolaa covid19asthmaandbiologicaltherapieswhatweneedtoknow AT rosenwasserlanny covid19asthmaandbiologicaltherapieswhatweneedtoknow AT sanchezborgesmario covid19asthmaandbiologicaltherapieswhatweneedtoknow AT virchowjchristian covid19asthmaandbiologicaltherapieswhatweneedtoknow AT yanezanahi covid19asthmaandbiologicaltherapieswhatweneedtoknow AT bernsteinjonathana covid19asthmaandbiologicaltherapieswhatweneedtoknow AT caraballoluisr covid19asthmaandbiologicaltherapieswhatweneedtoknow AT changyoonseok covid19asthmaandbiologicaltherapieswhatweneedtoknow AT chikhladzemanana covid19asthmaandbiologicaltherapieswhatweneedtoknow AT fiocchialessandro covid19asthmaandbiologicaltherapieswhatweneedtoknow AT gonzalezdiazsandranora covid19asthmaandbiologicaltherapieswhatweneedtoknow AT tannolucianakase covid19asthmaandbiologicaltherapieswhatweneedtoknow AT levinmichael covid19asthmaandbiologicaltherapieswhatweneedtoknow AT ortegamartelljoseantonio covid19asthmaandbiologicaltherapieswhatweneedtoknow AT passalacquagiovanni covid19asthmaandbiologicaltherapieswhatweneedtoknow AT pedendavidb covid19asthmaandbiologicaltherapieswhatweneedtoknow AT rouadiphilipw covid19asthmaandbiologicaltherapieswhatweneedtoknow AT sublettjamesl covid19asthmaandbiologicaltherapieswhatweneedtoknow AT wonggarywk covid19asthmaandbiologicaltherapieswhatweneedtoknow AT bleeckereugener covid19asthmaandbiologicaltherapieswhatweneedtoknow |